BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Longstreth GF, Anderson DS, Zisook DS, Shi JM, Lin JC. Low Rate of Cancer Detection by Colonoscopy in Asymptomatic, Average-Risk Subjects with Negative Results From Fecal Immunochemical Tests. Clin Gastroenterol Hepatol 2020;18:2929-2936.e1. [PMID: 32007541 DOI: 10.1016/j.cgh.2020.01.029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wassie MM, Young GP, Winter JM, Cock C, Bampton P, Rahman M, Heddle R, Fraser R, Meng R, Symonds EL. Multiple Negative Fecal Immunochemical Tests Reduce Risk of Advanced Neoplasia in a Colonoscopy Surveillance Program. Clin Gastroenterol Hepatol 2023:S1542-3565(23)00002-2. [PMID: 36610499 DOI: 10.1016/j.cgh.2022.12.024] [Reference Citation Analysis]
2 Goedert JJ, Wu Z, Yonehara CH, Frankland TB, Sinha R, Jones GS, Wan Y, Ravel J, Zhao N, Honda SA. Reusing a prepaid health plan's fecal immunochemical tests for microbiome associations with colorectal adenoma. Sci Rep 2022;12:14801. [PMID: 36045142 DOI: 10.1038/s41598-022-18870-w] [Reference Citation Analysis]
3 Gao S, Xue J, Wu X, Zhong T, Zhang Y, Li S. The relation of blood cell division control protein 42 level with disease risk, comorbidity, tumor features/markers, and prognosis in colorectal cancer patients. J Clin Lab Anal 2022;:e24572. [PMID: 35735582 DOI: 10.1002/jcla.24572] [Reference Citation Analysis]
4 Zhang X, Zhang Y, Gui X, Zhang Y, Zhang Z, Chen W, Zhang X, Wang Y, Zhang M, Shang Z, Xin Y, Zhang Y. Salivary Fusobacterium nucleatum serves as a potential biomarker for colorectal cancer. iScience 2022;25:104203. [DOI: 10.1016/j.isci.2022.104203] [Reference Citation Analysis]
5 Senore C, Zorzi M. Do We Need a New Paradigm for Assessing the Accuracy of Fecal Immunochemical Test Screening? Clin Gastroenterol Hepatol 2020;18:2873-5. [PMID: 32289539 DOI: 10.1016/j.cgh.2020.04.008] [Reference Citation Analysis]